STOCK COMPARISON
Medacta Group vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how Medacta Group (MOVE) and Abbott Laboratories (ABT) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Medacta Group trades at CHF 133 versus a fair value of CHF 79.97 (-40%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Medacta Group
MOVE.SW · CHF · Health Care
-40%
upside to fair value
overvalued
PriceCHF 133
Fair ValueCHF 79.97
Quality57/100
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$108
Fair Value$74.79
Quality67/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Medacta GroupAbbott Laboratories
Valuation
31.7×P/E (TTM)27.7×
5.04×P/S (TTM)3.89×
7.56×P/B3.36×
20.5×EV/EBITDA15.1×
—PEG1.47×
0.9%Dividend yield—
CHF 1.18Dividend per share—
Profitability
14%Net margin14%
16%Operating margin13%
23%Return on equity12%
8%Return on assets6%
Growth
13%Revenue growth (YoY)8%
16.3%Avg. growth/yr (3Y)0.5%
17.9%Avg. growth/yr (5Y)5.1%
Balance & size
0.25×Debt / equity0.19×
$3BMarket cap$175B
mixedGrowth qualityhealthy
Medacta Group leads: 7 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Medacta Groupof which business quality 58 · market factors 37
Abbott Laboratoriesof which business quality 66 · market factors 51
ProfitabilityMargins and returns on capital today
68
50
Quality GrowthAre margins and returns improving?
52
47
CashflowEarnings quality: real cash, not paper profit
46
71
Fin. StrengthBalance sheet, leverage, solvency risk
72
80
InvestmentDisciplined investing over empire-building
13
65
Low VolatilityCalm price path (market factor)
68
83
MomentumPrice trend over the last 3–12 months (market factor)
29
40
52W MomentumDistance to the 52-week high (market factor)
15
33
Net IssuanceBuybacks instead of dilution
80
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Medacta Group
DCF ModelsCHF 89.04
Earnings-BasedCHF 74.97
Dividend DiscountCHF 12.09
MultiplesCHF 88.39
Asset-BasedCHF 15.35
Growth DCFCHF 57.68
Economic ProfitCHF 55.59
Growth EarningsCHF 114
24 of 26 models see the stock below the current price.
Abbott Laboratories
DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Medacta Group
Bear CHF 38.00Fair Value CHF 79.97Bull CHF 138
CHF 133 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$108 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Medacta Group · Health Care
Quality score57 · above median
Fair value upside-40% · below median
Abbott Laboratories · Health Care
Quality score67 · Top 25%
Fair value upside-31% · below median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Medacta Group trades at CHF 133 versus a fair value of CHF 79.97 (-40%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Abbott Laboratories has the higher quality score (67/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
